Occupational Exposure to Pesticides in the Prognosis of Lymphomas (ProLyPhy)

Study of the Role of Occupational Exposure to Pesticides in the Prognosis of Lymphomas Diffuse Large B Cell in

The link between the products of synthetic chemistry and cancer is at the heart of much research. Recent work has identified the use of plant protection agents by farmers as a risk factor for developing non-Hodgkin lymphoma, including diffuse large B cell lymphoma (DLBCL) is the most common histology. Different biological models were used to understand the role of pesticides in lymphomagenesis. To summarize, most pesticides act at the cellular and molecular level, on different signaling pathways. After metabolized by cytochrome P450, these compounds generally become pro-oxidants. The increase in reactive oxygen species rate (SAR) causes the activation of signaling pathways involved in cell proliferation and survival. But deregulation of oxidative status does not in itself justify the specificity of the impact of pesticides on specific pathologies. Several agents have a genotoxic effect, others induce the activation of signaling pathways by binding to transcription factors and others have immunomodulating properties.

Study Overview

• Status: Terminated
• Conditions: Lymphoma Diffuse Large B-cell

Detailed Description

The link between the products of synthetic chemistry and cancer is at the heart of much research. Recent work has identified the use of plant protection agents by farmers as a risk factor for developing non-Hodgkin lymphoma, including diffuse large B cell lymphoma (DLBCL) is the most common histology. Different biological models were used to understand the role of pesticides in lymphomagenesis. To summarize, most pesticides act at the cellular and molecular level, on different signaling pathways. After metabolized by cytochrome P450, these compounds generally become pro-oxidants. The increase in reactive oxygen species rate (SAR) causes the activation of signaling pathways involved in cell proliferation and survival. But deregulation of oxidative status does not in itself justify the specificity of the impact of pesticides on specific pathologies. Several agents have a genotoxic effect, others induce the activation of signaling pathways by binding to transcription factors and others have immunomodulating properties.

Among these four mechanisms by which pesticides are involved in lymphomagenesis, two are also associated with resistance to chemotherapy. Thus, genotoxic agents leads the implementation process of DNA repair, used to repair genotoxic lesions induced by chemotherapeutic agents and evade apoptosis. On the other hand, to survive a high level of ROS, the tumor cell raises the level of antioxidant defenses, maintaining redox homeostasis and preventing oxidative stress. However, a high production of antioxidants constitutes a barrier to the effectiveness of anti-tumor agents which are effective in the generation of oxidative stress.

• Study Type: Observational
• Enrollment (Actual): 244

Contacts and Locations

Study Locations

• France
  • Montpellier, France, 34295
    • LAMURE

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 100 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Adults treated for diffuse large B-cell lymphoma:

Description

Inclusion Criteria:

Adults treated for diffuse large B-cell lymphoma:

• Diagnosed between 2010 and 2015
• Having received immuno-chemotherapy R-CHOP
• Supported in the health facilities of the Languedoc-Rousillon

Exclusion Criteria:

NA

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
pesticide exposure	The exposure measurement will be carried out using a self-administered questionnaire sent to patients on their professional activities. If farming a second questionnaire will further characterize the exposure to pesticides	1 day

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier
• Investigators: Principal Investigator: Sylvain LAMURE, University Hospital, Montpellier

Study record dates

Study Major Dates

• Study Start: July 1, 2015
• Primary Completion (Actual): October 1, 2017
• Study Completion (Anticipated): April 1, 2018

Study Registration Dates

• First Submitted: September 8, 2016
• First Submitted That Met QC Criteria: September 8, 2016
• First Posted (Estimate): September 13, 2016

Study Record Updates

• Last Update Posted (Actual): October 10, 2017
• Last Update Submitted That Met QC Criteria: October 9, 2017
• Last Verified: September 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma
• Other Study ID Numbers: 9668

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED